We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to target and kill cancer cells. We do this using our engineered autologous cell therapy, which we believe is a transformational approach to the treatment of cancer. Our therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors, or CARs, or T cell receptors, or TCRs, and then reinfusing the engineered T cells back into the patient. CARs can recognize native cancer antigens that are part of an intact protein presented on the cancer cell surface. TCRs broaden the therapeutic approach by recognizing fragments on the cancer cell surface derived from intracellular proteins. By combining both CAR and TCR approaches, we have generated and advanced a broad portfolio of product candidates to target both solid and hematological tumors.
Company profile
Ticker
KITE
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
13 Oct 17
UPLOAD
Letter from SEC
12 Oct 17
25-NSE
Exchange delisting
3 Oct 17
8-K
Completion of Acquisition or Disposition of Assets
3 Oct 17
POSASR
Automatic shelf registration (post-effective amendment)
3 Oct 17
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Oct 17
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Oct 17
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Oct 17
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Oct 17
SC 14D9/A
Tender offer solicitation (amended)
3 Oct 17
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|